




Serum Magnesium Levels in Neonatal Jaundice: Is There any Correlation Between Hypermagnesemia and Moderate to Severe Hyperbilirubinemia in Term Newborns?

Fahimeh Ehsanipour¹, Elahe Norouzi ^{2,*}, Nastaran Khosravi¹ and Hosna Mirfakhraee¹

¹Iran University of Medical Sciences, Tehran, Iran

²Rasoul-e-Akram Medical Center, Iran University of Medical Sciences, Tehran, Iran

*Corresponding author: Assistant Professor of Pediatrics, Neonatologist, Rasoul-e-Akram Medical Center, Iran University of Medical Sciences, Niayesh St., Sattarkhan Blvd., Tehran, Iran. Tel: +98-9123495772, Email: elahenorouzimd@gmail.com

Received 2019 May 23; Revised 2019 November 30; Accepted 2019 December 08.

Abstract

Background: Neonatal jaundice is a common major problem; on the other hand, it is suggested that there is a correlation between plasma magnesium concentrations and hyperbilirubinemia during the neonatal period.

Objectives: The study aims to validate a previously reported risk index for predicting the magnesium level of plasma for moderate to severe hyperbilirubinemia in infant neonates.

Methods: A cross-sectional correlation study was performed on 93 term newborns with indirect hyperbilirubinemia admitted in neonatology unit of a children hospital and plasma magnesium level of moderate to severe Neonatal hyperbilirubinemia were determined, and statistical analysis was performed.

Results: Authors did not find any statistically meaningful positive or negative correlation between plasma Mg level and bilirubin in patients studied; however, comparison of Mg level in two groups of severe and moderate hyperbilirubinemia showed decreased dispersion of medium Mg level in the severe group.

Conclusions: Serum magnesium concentration is not useful in anticipation of which newborn infant will develop hyperbilirubinemia.

Keywords: Newborn, Magnesium, Hyperbilirubinemia, Bilirubin, Jaundice

1. Background

Hyperbilirubinemia, a common problem in neonate infants (1-3), is seen in about 80% of preterm and 60% of term newborns during the first days of life (4, 5). Bilirubin is considered as a neurotoxic agent (3, 6), injures neural cell membranes and damages membrane enzymes and receptors (7-9), and results in neurologic deficit in infants (10).

Furthermore, structures such as N-methyl D-aspartate (NMDA) receptor, located in the synaptic surface of the cell membrane structure, is subjected to the bilirubin injury; therefore, neurologic development and learning and memory disorders in childhood is due.

Many reports have suggested magnesium (Mg) as a neuroprotective factor, which protects central nervous system against hypoxia, and comprises supportive effects of neurons (11-14). Physiologic effects of Mg are opposite of bilirubin neurotoxic effects (15, 16). Mg is one of the most important NMDA regulatory antagonists in the neural sur-

face, which reverses the damaging cell membrane mechanisms by receptor blocking, and finally, leads to neural system protection.

Hence, it seems that plasma Mg level manifests the metabolic and physiologic states of a neonate with hyperbilirubinemia.

2. Objectives

Although Mg regulatory and protective effects on the NMDA receptor is completely known, Mg and hyperbilirubinemia relation is not studied well. This study is designed to assess any relation between Mg plasma level and moderate to severe hyperbilirubinemia.

3. Methods

This was a correlation study carried out on 93 term neonates admitted to the Aliasghar Children Hospital

Neonatal Ward in Tehran, IR Iran, during Apr. to Sep. 2012. The inclusion criteria was moderate to severe hyperbilirubinemia required treatment in term neonates, according to Bhutani nomogram, nearly 16 to 20 mg/dL for patients with moderate hyperbilirubinemia, and more than 20 mg/dL for severely affected neonates. The exclusion criteria included anemia with hemoglobin less than 8.7 g/dL or hemolysis evidence, G6PD enzyme deficiency, red blood cell membrane disorders, MgSO₄ use in the prenatal period, and major congenital anomalies.

Every infant has undergone two blood sampling. Serum Mg level was analyzed by the Becton Dickinson Vacutainer system, France, measured by the Ion-selective electrode (ISE) method. Serum bilirubin was assayed with colorimetric method by the use of Diazotized Sulfanilic acid reaction; Roche diagnostic kit, USA.

Hyperbilirubinemia was classified into two groups of severe (total bilirubin more than 20 mg/dL) and moderate (total bilirubin \leq 20 mg/dL). Mg level greater than 2.3 mg/dL was defined as hypermagnesemia, and Mg level less than 1.5 mg/dL was assumed as hypomagnesemia.

Data analysis was performed by the use of SPSS 17. Various parameters co-efficient were assessed by the Pearson test. Group comparison was carried out by Ki square and independent *t*-test, according to the qualitative or quantitative nature of P value; and P values less than 0.05 were assumed statistically meaningful.

4. Results

Among 93 jaundiced term neonates with moderate to severe hyperbilirubinemia, 39% were female; and 61% were male. Moderate hyperbilirubinemia, in a study population, was 88.2% (82 patients), and frequency of severe hyperbilirubinemia was 11.8% (11 of 93 patients). Among the infants studied, medium serum bilirubin level was 18.29 ± 1.8 mg/dL (with range of 12.3 to 24 mg/dL), and medium plasma Mg level was 1.9 ± 0.3 mg/dL (range of 1.3 to 2.7 mg/dL).

In neonates with moderate hyperbilirubinemia, medium serum bilirubin was 17.7 ± 1.27 mg/dL, and medium infant age was 6.8 ± 3.9 days, with medium birth weight of 3018 ± 413 grams; medium plasma Mg level was 1.9 ± 0.3 mg/dL.

In neonates with severe hyperbilirubinemia, medium serum bilirubin was 22.11 ± 1.19 , medium infant age was 6.6 ± 3.3 days, and medium infant weight at birth was 3091 ± 639 grams; medium severe Mg level was 1.9 ± 0.2 mg/dL.

According to this study the relation of hyperbilirubinemia with infant sex ($P = 0.368$), neonate age ($P = 0.89$), and birth weight ($P = 0.63$) was not statistically meaningful.

Statistical analysis didn't reveal any meaningful correlation between hyperbilirubinemia and high plasma Mg level ($P = 0.368$), or low plasma Mg level ($P = 0.305$).

Comparison of Mg level in two groups of severe and moderate hyperbilirubinemia showed decreased dispersion of medium Mg level in the severe group, however, this finding is not statistically meaningful ($P > 0.05$).

5. Discussion

Magnesium, the second frequent intracellular cation, is essential for fetal growth, and Mg deficiency in pregnancy is associated with eclampsia or pre-eclampsia, premature labor, prolonged duration of maternal hospitalization, and infant low birth weight (15).

Relevant past studies have demonstrated neuroprotective effects of ionized Mg (11-14). On the other hand, neurotoxic property of indirect bilirubin (10) proposed the hypothesis about the relationship between plasma Mg and bilirubin level in hyperbilirubinemic newborn infants. Sapkota found a significant difference in the Mg concentrations before and after phototherapy correspondingly bilirubin levels before and after phototherapy and concluded that phototherapy could decrease serum Mg level as much as Bilirubin. He concluded that there was a positive relation between serum Mg and bilirubin levels and propounded that rising of Mg in hyperbilirubinemia might be a compensatory mechanism against toxic effects of bilirubin (16).

The recent study revealed the Mg level in infants with severe hyperbilirubinemia a little higher than the moderate hyperbilirubinemic group (1.90 ± 0.3 mg/dL and 1.91 ± 0.2 mg/dL, respectively), which was not statistically significant. Past studies propounded contradictory opinions on this subject. Dennerly et al., referred to a positive correlation of serum Mg level and hyperbilirubinemia severity; and thought that increased cell damage is the cause of hypermagnesemia. There are some reports representing that bilirubin not only harms neurons, but also affects other types of cells by their toxic effects (17).

Ilves et al. (18) and Engle and Elin (19) reported increased serum Mg level in asphyxia. Furthermore, Olofsson et al. (20), and Sarici et al. (21), thought that hypermagnesemia leads to acidosis and hypoxemia, which in turn, may cause irreparable effects in neural cells. Some researchers suggested ionized Mg as a NMDA receptor blocking ion. Hyperactivity of NMDA receptors on the neuron membrane, during the intrauterine period, leads to ischemic encephalopathy; bilirubin affects NMDA in this way, and magnesium ion acts as a neuroprotective substance by blocking the NMDA receptors in neural cells. In the animal models studied, increased bilirubin level

changed the membrane NMDA receptor activity and led to neuronal injuries (7-9, 22).

Sakamoto et al. (23), demonstrated that there isn't any association between plasma and cerebrospinal fluid Mg level in patients with cerebral injuries; this may be due to the blood brain barrier presence. This finding is compatible with our study results. On the other hand, Sarici et al. (24), explained that elevated plasma Mg level in neonatal diseases such as respiratory distress syndrome or hyperbilirubinemia is due to acidosis and hypoxia resulting from generalized cellular damage including erythrocytes and neurons and extracellular movement of principally intracellular Mg ion (24). In a study performed by Yasser et al., the mean levels of plasma Mg were significantly higher in hemolytic unconjugated hyperbilirubinemic neonates compared to controls and non-hemolytic cases, which was thought to be due to the extracellular movement of Mg from erythrocytes (25).

Pintov et al., did not find any significant correlation between the highest serum bilirubin concentrations and cord serum concentrations of zinc, magnesium, and copper. They concluded that cord serum concentrations of magnesium, zinc, and copper were not predictive that which newborns would develop hyperbilirubinemia; their report is coordinated with the recent study (26).

There are some other paradoxical reports in the literature review, which may be due to prematurity. Perveen et al., showed that copper and magnesium remained in cord blood plasma at much less concentrations compared with the mother throughout the last trimester suggesting that the gestational age may have a major role in plasma Mg level in neonates and resulting adverse effects of hyperbilirubinemia (27). Cultural and socioeconomic differences due to genetic, geographical, and nutritional diversity may be involved in the paradoxical results. Baig et al., studied on zinc, copper, magnesium, calcium, and phosphorous levels in maternal and cord blood and demonstrated that Mg levels were higher in Pakistani women's blood in comparison of cord blood (28).

5.1. Conclusions

Serum concentrations of magnesium were not profitable in the prediction of which neonates would develop moderate to severe indirect hyperbilirubinemia. Although, we did not find any statistically meaningful positive or negative correlations between plasma Mg level and bilirubin in patients studied; comparison of Mg level in two groups of severe and moderate hyperbilirubinemia showed decreased dispersion of medium Mg level in severe group.

It is recommended that plasma Mg levels need to be studied in jaundiced neonates in comparison to patients

without considerable jaundice; and also, plasma Mg levels in mothers of neonates with hyperbilirubinemia. Furthermore, comparison of NMDA receptor numbers in healthy and jaundiced neonates or animal models may be a subject of future studies.

Footnotes

Authors' Contribution: Study concept and design: Fahimeh Ehsanipour, Nastaran Khosravi, and Elahe Norouzi; acquisition of data: Hosna Mirfakhraee and Fahimeh Ehsanipour; analysis and interpretation of data: Hosna Mirfakhraee; drafting of the manuscript: Elahe Norouzi; critical revision of the manuscript for important intellectual content: Elahe Norouzi; statistical analysis: Hosna Mirfakhraee; administrative, technical, and material support: Fahimeh Ehsanipour; study supervision: Fahimeh Ehsanipour and Nastaran Khosravi

Conflict of Interests: We have no financial interests related to the material in the manuscript.

Ethical Approval: The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a prior approval by the Institution's Human Research Committee (IR.IUMS.REC.1391.4903).

Funding/Support: We did not have any financial support or grant regarding this study.

Informed Consent: In regards to the ethics of experimentation, informed consent was obtained from each patient's parent included in the study.

References

- Greenwald JL. Hyperbilirubinemia in otherwise healthy infants. *Am Fam Physician*. 1988;**38**(6):151-8. [PubMed: 3057839].
- Porter ML, Dennis BL. Hyperbilirubinemia in the term newborn. *Am Fam Physician*. 2002;**65**(4):599-606. [PubMed: 11871676].
- Behrman RE, Kliegman RM. *Nelson textbook of pediatrics*. 20th ed. Philadelphia: Saunders; 2016.
- College of Family Physicians of Canada. Approach to the management of hyperbilirubinemia in term newborn infants. *Paediatr Child Health*. 1999;**4**(2):161-70. [PubMed: 20212978]. [PubMed Central: PMC2828212].
- Melton K, Akinbi HT. Neonatal jaundice. Strategies to reduce bilirubin-induced complications. *Postgrad Med*. 1999;**106**(6):167-8-77-8. doi: 10.3810/pgm.1999.11.775. [PubMed: 10576009].
- Nuntnarumit P, Naka C. Comparison of the effectiveness between the adapted-double phototherapy versus conventional-single phototherapy. *J Med Assoc Thai*. 2002;**85** Suppl 4:S1159-66. [PubMed: 12549790].
- Cashore WJ. Bilirubin metabolism and toxicity in the newborn. In: Polin RA, Fox WW, editors. *Fetal and neonatal physiology*. Philadelphia: WB Sanders; 1998. p. 1493-8.
- Bratlid D. How bilirubin gets into the brain. *Clin Perinatol*. 1990;**17**(2):449-65. [PubMed: 2196140].
- Brodersen R. Bilirubin. Solubility and interaction with albumin and phospholipid. *J Biol Chem*. 1979;**254**(7):2364-9. [PubMed: 429290].

10. Provisional Committee for Quality Improvement and Subcommittee on Hyperbilirubinemia; American Academy of Pediatrics. Practice parameter: Management of hyperbilirubinemia in the healthy term newborn. *Pediatrics*. 1994;**94**(4 Pt 1):558–65. [PubMed: 7755691].
11. Hoffman DJ, Marro PJ, McGowan JE, Mishra OP, Delivoria-Papadopoulos M. Protective effect of MgSO₄ infusion on nmda receptor binding characteristics during cerebral cortical hypoxia in the newborn piglet. *Brain Res*. 1994;**644**(1):144–9. doi: [10.1016/0006-8993\(94\)90357-3](https://doi.org/10.1016/0006-8993(94)90357-3). [PubMed: 8032941].
12. McDonald JW, Silverstein FS, Johnston MV. Magnesium reduces N-methyl-D-aspartate (NMDA)-mediated brain injury in perinatal rats. *Neurosci Lett*. 1990;**109**(1-2):234–8. doi: [10.1016/0304-3940\(90\)90569-u](https://doi.org/10.1016/0304-3940(90)90569-u). [PubMed: 2179770].
13. Marret S, Gressens P, Gadisseux JF, Evrard P. Prevention by magnesium of excitotoxic neuronal death in the developing brain: an animal model for clinical intervention studies. *Dev Med Child Neurol*. 1995;**37**(6):473–84. doi: [10.1111/j.1469-8749.1995.tb12035.x](https://doi.org/10.1111/j.1469-8749.1995.tb12035.x). [PubMed: 7789657].
14. Thordstein M, Bagenholm R, Thiringer K, Kjellmer I. Scavengers of free oxygen radicals in combination with magnesium ameliorate perinatal hypoxic-ischemic brain damage in the rat. *Pediatr Res*. 1993;**34**(1):23–6. doi: [10.1203/00006450-199307000-00006](https://doi.org/10.1203/00006450-199307000-00006). [PubMed: 8356013].
15. Pathak P, Kapoor SK, Kapil U, Dwivedi SN. Serum magnesium level among pregnant women in a rural community of Haryana State, India. *Eur J Clin Nutr*. 2003;**57**(11):1504–6. doi: [10.1038/sj.ejcn.1601832](https://doi.org/10.1038/sj.ejcn.1601832). [PubMed: 14576766].
16. Sapkota NK. Effect of phototherapy on serum bilirubin and ionized magnesium level in hyperbilirubinemic neonates. *Innovare J Med Sci*. 2017;**5**(1):10–1.
17. Dennery PA, Seidman DS, Stevenson DK. Neonatal hyperbilirubinemia. *N Engl J Med*. 2001;**344**(8):581–90. doi: [10.1056/NEJM200102223440807](https://doi.org/10.1056/NEJM200102223440807). [PubMed: 11207355].
18. Ilves P, Kiisk M, Soopold T, Talvik T. Serum total magnesium and ionized calcium concentrations in asphyxiated term newborn infants with hypoxic-ischaemic encephalopathy. *Acta Paediatr*. 2000;**89**(6):680–5. doi: [10.1080/080352500750043990](https://doi.org/10.1080/080352500750043990). [PubMed: 10914962].
19. Engel RR, Elin RJ. Hypermagnesemia from birth asphyxia. *J Pediatr*. 1970;**77**(4):631–7. doi: [10.1016/s0022-3476\(70\)80205-0](https://doi.org/10.1016/s0022-3476(70)80205-0). [PubMed: 5465913].
20. Olofsson K, Matthiesen G, Rudnicki M. Whole blood ionized magnesium in neonatal acidosis and preterm infants: A prospective consecutive study. *Acta Paediatr*. 2001;**90**(12):1398–401. doi: [10.1080/08035250152708798](https://doi.org/10.1080/08035250152708798). [PubMed: 11853336].
21. Sarici SU, Serdar MA, Erdem G, Alpay F, Tekinalp G, Yurdakok M, et al. Plasma ionized magnesium levels in neonatal respiratory distress syndrome. *Biol Neonate*. 2004;**86**(2):110–5. doi: [10.1159/000078678](https://doi.org/10.1159/000078678). [PubMed: 15153707].
22. Hoffman DJ, Zanelli SA, Kubin J, Mishra OP, Delivoria-Papadopoulos M. The in vivo effect of bilirubin on the N-methyl-D-aspartate receptor/ion channel complex in the brains of newborn piglets. *Pediatr Res*. 1996;**40**(6):804–8. doi: [10.1203/00006450-199612000-00005](https://doi.org/10.1203/00006450-199612000-00005). [PubMed: 8947954].
23. Sakamoto T, Takasu A, Saitoh D, Kaneko N, Yanagawa Y, Okada Y. Ionized magnesium in the cerebrospinal fluid of patients with head injuries. *J Trauma*. 2005;**58**(6):1103–9. doi: [10.1097/01.ta.0000169950.51735.c4](https://doi.org/10.1097/01.ta.0000169950.51735.c4). [PubMed: 15995455].
24. Sarici SU, Serdar MA, Erdem G, Alpay F. Evaluation of plasma ionized magnesium levels in neonatal hyperbilirubinemia. *Pediatr Res*. 2004;**55**(2):243–7. doi: [10.1203/01.PDR.0000103874.01584.F3](https://doi.org/10.1203/01.PDR.0000103874.01584.F3). [PubMed: 14630992].
25. Yasser A, Sultan A, Sultan S. Hyperbilirubinemia in fullterm neonatal unconjugated hyperbilirubinemia. *AAMJ*. 2013;**11**(3):97–108.
26. Pintov S, Kohelet D, Arbel E, Goldberg M. Predictive inability of cord zinc, magnesium and copper levels on the development of benign hyperbilirubinemia in the newborn. *Acta Paediatr*. 1992;**81**(11):868–9. doi: [10.1111/j.1651-2227.1992.tb12125.x](https://doi.org/10.1111/j.1651-2227.1992.tb12125.x). [PubMed: 1467607].
27. Perveen S, Altaf W, Vohra N, Bautista ML, Harper RG, Wapnir RA. Effect of gestational age on cord blood plasma copper, zinc, magnesium and albumin. *Early Hum Dev*. 2002;**69**(1-2):15–23. doi: [10.1016/s0378-3782\(02\)00024-5](https://doi.org/10.1016/s0378-3782(02)00024-5). [PubMed: 12324179].
28. Baig S, Hasnain NU, Ud-din Q. Studies on Zn, Cu, Mg, Ca and phosphorus in maternal and cord blood. *J Pak Med Assoc*. 2003;**53**(9):417–22. [PubMed: 14620318].